About us

Jean-Michel has over 25 years of experience in the pharmaceutical and biotechnology industries with a sustained global track record of success in commercial operations as well as in capital raising, US and European public offerings, business development and M&A. He served as VP for North America Oncology at Eli Lilly and, prior to this, as Chair of the Eli Lilly UK Board and was Chief Marketing Officer at GE Healthcare’s Global Headquarters. Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the boards of Kymab and Immunocore. He currently serves on the boards of Malin PLC, Exact Therapeutics AS, Eracal Therapeutics and Sophia Genetics SA.

Brings a wealth of experience from the sector through multiple roles across large pharma and clinical stage biotechnology companies, driving clinical development and substantial fundraises.

Lindy is an internationally recognised immunologist in the field of tumour therapy and co-founder of Scancell. She has worked for over 25 years in translational research, developing products for clinical trials including monoclonal antibodies and cancer vaccines. She has a personal Chair in Cancer Immunotherapy in the Department of Clinical Oncology at the University of Nottingham.

Sath is an experienced finance professional with over 15 years of experience across healthcare in FTSE and NASDAQ listed companies, investment banking and audit. Before joining Scancell, Sath was CFO for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. Prior to that, Sath worked at Reckitt where he was Finance Director for Group Reporting and subsequently for eCommerce in Reckitt’s Health Division. Sath has also held senior positions at BTG plc and, earlier in his career, he was an equity research analyst in the healthcare team at Nomura and prior to that an auditor at KPMG. Sath earned a BSc in Pharmacology from King’s College, London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath is also a Non-Executive member of the audit committee at The Institute of Cancer Research.

Martin is a founder, director and partner of Vulpes Investment Management, which manages a number of funds including the Vulpes Life Sciences Fund. He has over 30 years’ experience in investment banking and fund management, and has been an investor in life sciences and biotech for nearly 20 years. Martin’s other directorships are Oxford Biomedica plc, Proteome Sciences plc and Chronos Therapeutics Limited.

Susan is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including Managing Director of Equity Capital Markets at Citigroup Global Markets Limited/Salomon Smith Barney and most recently until 2018, Managing Director at Torreya Partners. Susan is currently Non-Executive Director of MiNA Therapeutics, Non-Executive Director of Exploristics, Advisor at Oxford Science Enterprises and Member of the CW+ NHS Hospital Innovation Advisory Board. Susan has a BSc in Economics from University College London and a MSc in Economics from the London School of Economics.

Dr Ney has over thirty years’ experience in the pharmaceutical and biotechnology industry, including twenty years in senior leadership roles that also encompassed Executive and Non-Executive Board positions. She has broad experience of biologic and small molecule drug development across a range of therapeutic areas having been Director of Drug Development and on the Board of Celltech plc and later Chief Operating Officer and Executive Director of Antisoma plc. Most recently, she was Chief Executive Officer of Genkyotex SA. She was a on the board of Discuva Ltd and is currently a Non-Executive Director of Proteome Sciences plc and also a member of the Board of Governors of the University of Plymouth.

Florian is a highly accomplished life sciences professional who brings over 20 years of leadership and investment experience across established pharmaceutical companies, start-ups and healthcare investment organisations. He is currently on the investment team at Redmile, an investment firm that focuses on the healthcare sector. Prior to joining Redmile, Florian has worked at Apax Partners, DBV technologies, CDC Innovation Capital and co-founded and served as CEO of Concilio. Florian holds a BA (hons) in Physiology from Oxford University, as well as a medical degree from Imperial College London School of Medicine.

Nermeen has over 25 years of healthcare industry experience in senior leadership positions at global biopharmaceutical companies, business consultancy and clinical trial services. She brings deep expertise in clinical trial planning and medical affairs, with a strong track record in the execution of global drug development programmes including numerous registration studies in oncology. Nermeen has experience of building cross-functional global teams and progressing clinical assets through to regulatory and commercial success in several companies including BTG Ltd, Atlantic Healthcare plc and most recently at Relief Therapeutics. Dr Varawalla earned her MD from the University of Mumbai, followed by a PhD from the University of Oxford, UK, where she was a Rhodes Research Fellow. She also holds an MBA from INSEAD.

Mandeep brings more than 10 years of experience in business development and has previously held roles at leading UK biotech companies including at Abcam, where she covered the cancer portfolio, Cancer Research Technology, where she was involved in antibody out licensing, and Isogenica, where she was involved in making deals around the antibody platform, including a multi-target deal with BioNTech. Mandeep joins Scancell from ImaginAb where she held the role of Director of Business Development and worked on a number of out-licensing deals in cell therapy, vaccines and antibodies. She holds a PhD in Cell and Molecular Biology and a Master’s degree in Molecular Pathology and Toxicology from the University of Leicester, UK.

Callum brings over 15 years of experience in vaccine research and development. Before joining Scancell, he he served as a Product Development Consultant and held the role of Technical Transfer and Formulation Development Manager at Allergy Therapeutics, where he led product development and CMC activities for the VLP Peanut project. He holds a PhD in Molecular Microbiology and a BSc in Biochemistry from Heriot-Watt University.

Adrian joined Scancell from Mereo BioPharma where he was Head of Small Molecule CMC (Chemistry, Manufacturing and Controls), managing outsourced GMP manufacturing activities. Prior to this, Adrian was New Product Development Director at Juniper Pharmaceuticals  and has previously held further CMC positions at Circassia, Shire Pharmaceuticals, Prosidion, Evotec and OSI Pharmaceuticals, totalling 20 years of development expertise including the delivery of multiple, complex GMP drug products. Adrian holds a PhD in Physical Organic/Analytical Chemistry from The Open University, following a MSc in Advanced Analytical Chemistry from the University of Bristol.

Samantha joined Scancell from Immunocore where she held several positions including Head of T Cell Cloning and Group Leader. While at Immunocore, Samantha was responsible for the generation of the in house T cell cloning method and biological molecule discovery which made significant contributions to the current Immunocore oncology pipeline. Prior to this, Samantha held a number of positions at Medigene, Avidex, NIBSC and GSK. Samantha holds a PhD from University College London in Immunology/Haematology, following an BSc Honours Degree in Microbiology from the University of Sheffield.

Alex brings over 10 years of professional experience. Familiar with financing transactions, collaborations and key processes, he has delivered timely reporting and assumed a wide range of responsibilities at clinical and commercial stage Nasdaq listed biotechnology companies. He joins Scancell from Immunocore, where he was Director of External Reporting & SOX Compliance and instrumental in the implementation of effective controls and commercial accounting. Alex previously worked at Adaptimmune and Johnson & Johnson after qualifying as a chartered accountant at KPMG. He holds an ACA qualification from the ICAEW and an MA in English Literature from the University of Edinburgh.